logo
What You Need to Know About Conjunctivitis

What You Need to Know About Conjunctivitis

Health Linea day ago
Key takeaways
Conjunctivitis, commonly called pink eye, involves inflammation of the membrane that covers the eye, leading to redness, discomfort, and discharge in the affected eye.
Pink eye can result from infections (bacterial or viral), allergies, or irritants. Contagious types can spread easily through contact.
Treatment varies depending on the cause, ranging from rinsing for chemical irritations to antibiotics for bacterial infections, antihistamines for allergies, or supportive care for viral cases.
When you have pink eye, blood vessels in your conjunctiva become inflamed. This gives your eye the red or pink color that's commonly associated with conjunctivitis.
There are a few different types of pink eye that come with varying symptoms and treatments.
Pink eye symptoms
Different types of pink eye can come with slightly different symptoms, but in general, it's important to talk with a doctor if you start to experience:
pink or red-toned eyes
a gritty feeling in your eyes
watery or thick discharge that builds up on your eyes at night
itchiness in your eyes
abnormal amount of tears
Types and causes
In general, there are three main categories of pink eye:
infectious
allergic
chemical
Infectious conjunctivitis
Infectious pink eye comes in a few different types, including:
bacterial
viral
Bacterial pink eye is caused by staphylococcal or streptococcal bacteria. It typically occurs due to things like touching your eyes with unclean hands, sharing makeup, or having physical contact with someone who may also have conjunctivitis.
Viral pink eye is usually caused by common cold viruses. It can occur if someone with an upper respiratory infection coughs or sneezes close to you. It can also occur when you have a cold virus yourself and blow your nose too hard. This can push the infection from your respiratory system to your eyes.
Allergic conjunctivitis
Most people with allergic pink eye have seasonal allergies. They can get pink eye if they come in contact with a substance they're allergic to, like pollen.
It's also possible to develop an allergic type of pink eye called giant papillary conjunctivitis if you wear hard contact lenses, or soft contact lenses that aren't replaced frequently enough.
Chemical conjunctivitis
You can get pink eye from irritants such as:
How contagious is pink eye?
Bacterial and viral pink eye are very contagious.
Pink eye is very easily spread from person to person. For instance, if someone with viral pink eye touches their eye and then touches your hand, and you touch your eyes, there's a chance you could get pink eye as well.
Pink eye is typically contagious for as long as the person is having symptoms.
Images of pink eye
How is pink eye diagnosed?
It's typically not difficult for a healthcare professional to diagnose pink eye. They will usually be able to tell if you have pink eye simply by asking you a few questions and looking at your eyes.
For example, a healthcare professional might ask you if your eyes are itchy and whether you have watery or thick discharge. They might also ask if you're experiencing symptoms of a common cold, hay fever, or asthma.
They may also perform a few tests, including:
a vision test to see whether your vision has been affected
external eye tissue examination, including the conjunctiva, using bright light and magnification
examination of the inner eye to make sure no other tissues have been affected
conjunctival tissue smear, which is typically done when a person is dealing with chronic pink eye, or the condition is not improving with treatment
Treatment for pink eye
Treatment of conjunctivitis depends on what's causing it.
Chemical conjunctivitis
Rinsing your eye with saline is one way to help ease symptoms if you're dealing with chemical pink eye. Topical steroids may also be prescribed if the case is severe enough.
Bacterial conjunctivitis
For a bacterial infection, antibiotics are the most common method of treatment. Adults usually prefer eye drops. For children, ointment might be a better choice because it's easier to apply.
With the use of antibiotic medication, your symptoms will probably start to disappear in just a few days — but it's important to finish your entire prescription to lessen the risk of pink eye coming back.
Viral conjunctivitis
Most of the time, viral conjunctivitis is caused by the same viruses that cause the common cold. These cold viruses don't currently have any treatments, but symptoms are usually mild and resolve on their own in 7 to 10 days.
In rare cases, other viruses like the herpes simplex or varicella-zoster virus can be involved, which can cause more serious infections. These viruses do have antiviral treatments, but these treatments can only be used for these specific types of viral infections.
In the meantime, using a warm compress, or a cloth moistened with warm water, can help soothe your symptoms.
Allergic conjunctivitis
To treat pink eye caused by an allergen, your healthcare professional will probably prescribe an antihistamine to stop the inflammation.
Loratadine (Claritin) and diphenhydramine (Benadryl) are antihistamines that are available as over-the-counter medications. They may help clear your allergic symptoms, including allergic pink eye.
Other treatments include antihistamine eye drops or anti-inflammatory eye drops.
Home remedies
In addition to using a warm compress, you can also purchase eye drops at your local drugstore that mimic your own tears. These may help relieve your pink eye symptoms.
It's also a good idea to stop wearing contact lenses until your pink eye completely clears up.
How can you prevent conjunctivitis?
Practicing good hygiene is one of the best ways to avoid and stop the transmission of conjunctivitis:
Avoid touching your eyes with unwashed hands whenever possible.
Wash your hands often and thoroughly with soap and water.
Only use clean tissues and towels to wipe your face and eyes.
Try not to share cosmetics, especially eyeliner or mascara, with others.
Wash pillowcases frequently.
If your healthcare professional thinks your contact lenses are contributing to your pink eye, they may recommend switching to another type of contact lens or disinfectant solution.
They may also suggest cleaning or replacing your contact lenses more frequently, or that you stop wearing contact lenses indefinitely (or at least until your eye heals).
Avoiding poorly fitted contact lenses and decorative contact lenses may also decrease your risk for pink eye.
Preventing the transmission of pink eye
If you already have pink eye, you can help keep your friends and family safe by doing the following:
Wash your hands regularly.
Avoid sharing towels or washcloths.
Change your towel and washcloth daily.
Replace eye cosmetics after your infection clears.
Follow your healthcare professional's advice on contact lens care.
Take any medication your doctor has given you as prescribed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models
Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models

Associated Press

timea minute ago

  • Associated Press

Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models

SAN DIEGO--(BUSINESS WIRE)--Jul 23, 2025-- the leading R&D procurement orchestration platform for the life sciences, today announced a major expansion of its Tumor Model Finder (TMF) following a strategic partnership with XenoSTART, a global leader in patient-derived xenograft (PDX) model development and testing. The addition of hundreds of unique and high-demand XenoSTART models pushes the TMF past a milestone of 10,000 searchable oncology models, giving cancer researchers unprecedented access to diverse and clinically relevant tools. 'Pharma discovery teams often face critical delays accessing translational research partners with deeply characterized PDX models that accurately reflect real-world patient disease complexity,' said Michael J. Wick, PhD, Chief Scientific Officer at XenoSTART. 'By joining the marketplace, XenoSTART eliminates this significant barrier, providing immediate access to our highly relevant, patient-derived tumor models that are directly linked to our global clinical network. This integration empowers drug developers to confidently accelerate therapeutic decision-making and precisely guide their translational strategies—ultimately speeding effective cancer treatments to patients.' Tumor Model Finder is a centralized, AI-powered platform that aggregates and standardizes tumor model data from 20+ leading CROs. It allows researchers to search, compare, and source PDX, CDX, organoid, and cell line models—spanning 17 cancer types—through a single workflow. The platform also includes drug response profiles, genomic alterations (e.g., KRAS, BRAF mutations), and RNA seq-based gene expression data to support informed model selection and study design. 'XenoSTART's contribution significantly boosts the depth and quality of our TMF offerings,' said Javier Pineda, PhD, Director of Preclinical AI at 'Researchers can now find models with richer data and greater relevance to their specific cancer studies.' This collaboration also highlights the translational impact of START's global research ecosystem. With patient-derived tissue samples sourced from START's expansive oncology trial network, XenoSTART's models provide critical continuity between preclinical evaluation and clinical trial execution—helping pharmaceutical companies make faster, more confident decisions in oncology drug development. To learn more or schedule a demo of the Tumor Model Finder, email [email protected]. About is the life-science industry's premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world's top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Visit to discover how we accelerate science. About XenoSTART Founded in 2007, XenoSTART is a translational research organization dedicated to advancing oncology drug development through clinically relevant preclinical cancer models. The XenoSTART Patient-Derived Xenograft (XPDX) platform features more than 2,800 models across a broad range of tumor types and disease stages sourced from patients treated at START's domestic and international cancer centers. Models are deeply characterized using histologic analysis, DNA/RNA sequencing, and in vivo drug sensitivity testing, and are clinically annotated with the donor patient's treatment history and clinical outcome. By bridging real-world tumor biology with rigorous preclinical science, XenoSTART enables pharmaceutical partners to make smarter, faster decisions from bench to bedside. Learn more about XenoSTART at View source version on CONTACT: Sean Preci +1 877-644-3044 [email protected] XenoSTART Lauren Panco 609-216-4920 KEYWORD: EUROPE UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: OTHER HEALTH RESEARCH PHARMACEUTICAL ONCOLOGY TECHNOLOGY ARTIFICIAL INTELLIGENCE GENETICS HEALTH TECHNOLOGY SCIENCE BIOTECHNOLOGY OTHER SCIENCE HEALTH SOURCE: Copyright Business Wire 2025. PUB: 07/23/2025 07:55 AM/DISC: 07/23/2025 07:55 AM

Avel eCare Appoints Martainn Lenhardt as Chief Financial Officer to Lead Financial Strategy Amid Rapid Growth and Innovation
Avel eCare Appoints Martainn Lenhardt as Chief Financial Officer to Lead Financial Strategy Amid Rapid Growth and Innovation

Associated Press

time3 minutes ago

  • Associated Press

Avel eCare Appoints Martainn Lenhardt as Chief Financial Officer to Lead Financial Strategy Amid Rapid Growth and Innovation

SIOUX FALLS, SD / ACCESS Newswire / July 23, 2025 / Avel eCare, a leading provider of telemedicine services in the United States, today announced the appointment of Martainn Lenhardt as Chief Financial Officer (CFO). Lenhardt brings over 20 years of healthcare finance experience to the role, where he will oversee Avel's financial strategy, operations, and performance during a pivotal era of innovation and nationwide expansion. Lenhardt joins Avel eCare following his tenure as VP of Finance at Lyric and senior leadership roles at Change Healthcare, where he managed a $480 million business unit and was instrumental in driving growth and improving margins. He is widely recognized for his expertise in strategic growth, mergers and acquisitions, and optimizing global operations. His ability to turn complexity into opportunity and build agile, purpose-driven teams will be instrumental in advancing Avel's mission. 'Avel eCare is transforming how healthcare is delivered across the country,' said Lenhardt. 'It's an honor to join this team and help scale a model that brings high-quality, virtual care to every corner of the nation.' This appointment comes at a time of unprecedented momentum for Avel eCare. In the past two years alone, Avel has launched new service lines, secured exclusive partnerships with organizations like Amwell and Cibolo Health, and expanded services to more than 46 states. The company continues to innovate with in-ambulance telehealth, ICU solutions, and programs that support EMS, law enforcement, and correctional health, making care more accessible, cost-effective, and consistent, especially in rural and underserved areas. The new CFO joins an accomplished executive team committed to advancing healthcare access and outcomes across the country. Avel's leadership includes: About Avel eCare Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel's board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it's needed most. Learn more at: Media Contact: Jessica Gaikowski Avel eCare [email protected] SOURCE: Avel eCare press release

The world should strive to end PEPFAR
The world should strive to end PEPFAR

Washington Post

time3 minutes ago

  • Washington Post

The world should strive to end PEPFAR

Last week, the President's Emergency Plan for AIDS Relief narrowly escaped a devastating $400 million budget cut thanks to Republican Sens. Susan Collins (Maine) and Lisa Murkowski (Alaska), who voted alongside their Democratic colleagues to protect the program. That was a relief: Since its creation under President George W. Bush in 2003, the anti-HIV/AIDS program has saved an estimated 26 million lives and enabled 7.8 million babies to be born HIV-free.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store